
January/February 2006
David Hussong, Ph.D., and Robert Mello, Ph.D.
New Drug Microbiology Staff, Office of Pharmaceutical Science, Center for Drug Evaluation of Research
U.S. Food and Drug Administrations
Arwa El Hagrasy, Shih-Ying Chang, Divyakant Desai, and San Kiang
Bristol-Myers Squibb Company
Bernard A. Olsen and Douglas E. Kiehl
Lilly Research Laboratories
Eli Lilly and Company
1Nicholas Bodor and 2Peter Buchwald
1Center for Drug Discovery, University of Florida
2IVAX Research, Inc.
Rafik H. Bishara
Carey Newton, CIH, MSPH
Eli Lilly & Company
Yihong Qiu
Global Formulation Sciences, Global Pharmaceutical Research and Development
Abbott Laboratories
Adam Goldstein, David Schieche, Amy Manocchi, Ravi Samavedam, Lindsay Wilkinson
Amgen, Inc.
Robert A. Carlton
Investigator, Physical Properties, GlaxoSmithKline
Tsu-shun Lee, Ph.D.
Wyeth Vaccine Research
Jean M. Surian, Ph.D.
Pharmaceutical and Analytical R&D
AstraZeneca Pharmaceuticals
Anthony E. Dowrey, Gloria M. Story, and Curtis Marcott, Ph.D.
The Procter & Gamble Company
Deborah E. Mentel
Pfizer Global Research & Development
Peter Haddock, Ph.D.
Pfizer Global Research and Development
Narlin Beaty, Ph.D.
Sublimation Science